Terms: = Prostate cancer AND ACVR2A, ACVR2, 92, ENSG00000121989, ACTRII, P27037 AND Treatment
1631 results:
1. Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT.
Rosar F; Burgard C; David S; Marlowe RJ; Bartholomä M; Maus S; Petto S; Khreish F; Schaefer-Schuler A; Ezziddin S
Sci Rep; 2024 May; 14(1):11271. PubMed ID: 38760451
[TBL] [Abstract] [Full Text] [Related]
2. On the necessity of specialized knowledge-based models for SBRT prostate treatments plans.
Scaggion A; Cavinato S; Dusi F; El Khouzai B; Guida F; Paronetto C; Rossato MA; Sapignoli S; Scott ASA; Sepulcri M; Paiusco M
Phys Med; 2024 May; 121():103364. PubMed ID: 38701626
[TBL] [Abstract] [Full Text] [Related]
3. Identification and Quantification of Radiotherapy-related Protein Expression in cancer Tissues Using the Qupath Software and Prediction of treatment Response.
Hasegawa T; Someya M; Tsuchiya T; Kitagawa M; Fukushima Y; Gocho T; Mafune S; Okuda R; Kaguchi J; Ohguro A; Kamiyama R; Ashina A; Toshima Y; Hirohashi Y; Torigoe T; Sakata KI
In Vivo; 2024; 38(3):1470-1476. PubMed ID: 38688633
[TBL] [Abstract] [Full Text] [Related]
4. prostate-Specific Antigen Screening and 15-Year prostate cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial.
Martin RM; Turner EL; Young GJ; Metcalfe C; Walsh EI; Lane JA; Sterne JAC; Noble S; Holding P; Ben-Shlomo Y; Williams NJ; Pashayan N; Bui MN; Albertsen PC; Seibert TM; Zietman AL; Oxley J; Adolfsson J; Mason MD; Davey Smith G; Neal DE; Hamdy FC; Donovan JL;
JAMA; 2024 May; 331(17):1460-1470. PubMed ID: 38581198
[TBL] [Abstract] [Full Text] [Related]
5. Patient-Reported Outcome Measures Following Hyperbaric Oxygen Therapy for Radiation Cystitis: Early Results From the Multicenter Registry for Hyperbaric Oxygen Therapy.
Moses RA; Hunter AE; Brandes ER; Zhang Z; Rees JR; Peacock JL; Bihrle W; Sethuraman K; Weaver LK; Buckey JC
J Urol; 2024 Jun; 211(6):765-774. PubMed ID: 38573938
[TBL] [Abstract] [Full Text] [Related]
6. Machine Learning-Based Prediction of Hospitalization During Chemoradiotherapy With Daily Step Counts.
Friesner ID; Feng J; Kalnicki S; Garg M; Ohri N; Hong JC
JAMA Oncol; 2024 May; 10(5):642-647. PubMed ID: 38546697
[TBL] [Abstract] [Full Text] [Related]
7. Net survival of men with localized prostate cancer after LDR brachytherapy.
Uribe-Lewis S; Uribe J; Deering C; Langley S; Higgins D; Whiting D; Metawe M; Khaksar S; Mehta S; Mikropoulos C; Otter S; Perna C; Langley S
Brachytherapy; 2024; 23(3):329-334. PubMed ID: 38538414
[TBL] [Abstract] [Full Text] [Related]
8. Brachytherapy for favorable prognostic prostate cancer in men up to 60 years of age: Long term follow-up.
Jacques J; Sahki N; Meknaci É; Eschwege P; Peiffert D; Demogeot N
Brachytherapy; 2024; 23(3):301-308. PubMed ID: 38480107
[TBL] [Abstract] [Full Text] [Related]
9. Value of next generation sequencing (NGS) testing in advanced cancer patients.
Ortendahl JD; Cuyun Carter G; Thakkar SG; Bognar K; Hall DW; Abdou Y
J Med Econ; 2024; 27(1):519-530. PubMed ID: 38466204
[TBL] [Abstract] [Full Text] [Related]
10. Diagnostic value of
Guo S; Zhou C; Zhang Y; Wang D; Niu T; Zhou F
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Dec; 48(12):1812-1819. PubMed ID: 38448374
[TBL] [Abstract] [Full Text] [Related]
11. Partial gland ablation with high intensity focal ultrasound impact on genito-urinary function and quality of life: our initial experience.
Fugaru I; Bouhadana D; Marcq G; Moryousef J; Rompré-Brodeur A; Meng A; Loutochin O; Loutochin G; Anidjar M; Bladou F; Sanchez-Salas R
Can J Urol; 2024 Feb; 31(1):11784-11792. PubMed ID: 38401258
[TBL] [Abstract] [Full Text] [Related]
12. Development of CD46 targeted alpha theranostics in prostate cancer using
Bobba KN; Bidkar AP; Wadhwa A; Meher N; Drona S; Sorlin AM; Bidlingmaier S; Zhang L; Wilson DM; Chan E; Greenland NY; Aggarwal R; VanBrocklin HF; He J; Chou J; Seo Y; Liu B; Flavell RR
Theranostics; 2024; 14(4):1344-1360. PubMed ID: 38389832
[No Abstract] [Full Text] [Related]
13. Systemic interrogation of immune-oncology-related proteins in patients with locally advanced prostate cancer undergoing androgen deprivation and intensity-modulated radiotherapy.
Guldvik IJ; Ramberg H; Kristensen G; Røder A; Mills IG; Lilleby W; Taskén KA
World J Urol; 2024 Feb; 42(1):95. PubMed ID: 38386171
[TBL] [Abstract] [Full Text] [Related]
14. Medication-based Comorbidity Measures and prostate cancer treatment Selection.
Tiruye T; O'Callaghan M; FitzGerald LM; Moretti K; Jay A; Higgs B; Kichenadasse G; Caughey G; Roder D; Beckmann K
Clin Genitourin Cancer; 2024 Apr; 22(2):599-609.e2. PubMed ID: 38369388
[TBL] [Abstract] [Full Text] [Related]
15. Revolutionizing localized prostate cancer treatment: Stereotactic radiotherapy "Moroccan experience".
Naim A; Lahlou Z; Kaanouch O; Heddat A; Mansouri S
Arch Ital Urol Androl; 2024 Feb; 96(1):12104. PubMed ID: 38363238
[TBL] [Abstract] [Full Text] [Related]
16. Salvage vesiculectomy for local prostate cancer recurrence: surgical technique and early post-operative outcomes.
Giesen A; Van den Broeck T; Develtere D; Raskin Y; Wymer K; Eden C; Claessens M; Hente R; Rans K; Berghen C; De Meerleer G; Langley S; Karnes RJ; Heidenreich A; Pfister D; Joniau S
World J Urol; 2024 Feb; 42(1):81. PubMed ID: 38358521
[TBL] [Abstract] [Full Text] [Related]
17. Secondary bladder and colorectal cancer after treatments for prostate cancer: A population based study.
Bárcena PGQ; Aprikian AG; Dragomir A
Cancer Med; 2024 Feb; 13(3):e6922. PubMed ID: 38351647
[TBL] [Abstract] [Full Text] [Related]
18. Comparing the use of aggressive end-of life care among frail and non-frail patients with cancer using a claims-based frailty index.
Sachdev R; Shearn-Nance G; Vu L; Bensken WP; Douglas SL; Koroukian SM; Rose J
J Geriatr Oncol; 2024 Mar; 15(2):101706. PubMed ID: 38320468
[TBL] [Abstract] [Full Text] [Related]
19. Quantified treatment effect at the individual level is more indicative for personalized radical prostatectomy recommendation: implications for prostate cancer treatment using deep learning.
Pan H; Wang J; Shi W; Xu Z; Zhu E
J Cancer Res Clin Oncol; 2024 Feb; 150(2):67. PubMed ID: 38302801
[TBL] [Abstract] [Full Text] [Related]
20. Activation of cytotoxic lymphocytes through CD6 enhances killing of cancer cells.
Gurrea-Rubio M; Wu Q; Amin MA; Tsou PS; Campbell PL; Amarista CI; Ikari Y; Brodie WD; Mattichak MN; Muraoka S; Randon PM; Lind ME; Ruth JH; Mao-Draayer Y; Ding S; Shen X; Cooney LA; Lin F; Fox DA
Cancer Immunol Immunother; 2024 Jan; 73(2):34. PubMed ID: 38280067
[TBL] [Abstract] [Full Text] [Related]
[Next]
